Transgene Biotek is currently trading at Rs. 3.34, up by 0.15 points or 4.70% from its previous closing of Rs. 3.19 on the BSE.
The scrip opened at Rs. 3.34 and has touched a high and low of Rs. 3.34 and Rs. 3.34 respectively. So far 52984 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 6.85 on 26-Jun-2020 and a 52 week low of Rs. 2.75 on 20-Mar-2020.
Last one week high and low of the scrip stood at Rs. 3.67 and Rs. 3.03 respectively. The current market cap of the company is Rs. 25.31 crore.
The promoters holding in the company stood at 23.64%, while Non-Institutions held 76.36%.
Transgene Biotek has entered into an agreement with NeoDeL Pharma to support NeoDeL's Covid Vaccine project by formulating that company's Covid Vaccine, 'NeoCoVTM' for it to be administered in the form of oral and nasal drops.
NeoDeL Pharma has entered into an agreement with a renowned university in USA which has developed a novel Covid vaccine. NeoDeL is to seek requisite regulatory approvals in India for NeoC0VTM to be manufactured and marketed globally. Transgene provides support to NeoDeL through its novel delivery platform by formulating NeoCoV for it to be administered either as oral or nasal drops, first of its kind in the world. Transgene is to receive compensation through a combination of milestone payments, equity and royalty on sales.
Transgene Biotek (TBL) is engaged in manufacturing drugs for:New Drug Delivery System (NDDS)-Oral Delivery of Insulin,Oral Delivery Hepatitis B Vaccine and Pegylation of Protein Drugs.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 458.00 |
| Indegene | 529.65 |
| CMS Info Systems | 290.00 |
| JITF Infralogistics | 307.90 |
| Sagility | 44.18 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: